Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.006 AUD | 0.00% | 0.00% | -45.45% |
May. 14 | Bioxyne to Release Shares from Escrow; Shares Up 17% | MT |
May. 14 | Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia | MT |
Sales 2022 | 2.48M 1.66M | Sales 2023 | 5.3M 3.54M | Capitalization | 38.03M 25.37M |
---|---|---|---|---|---|
Net income 2022 | - 0 | Net income 2023 | -1M -667K | EV / Sales 2022 | 2.22 x |
Net cash position 2022 | 2.17M 1.45M | Net cash position 2023 | 3.29M 2.19M | EV / Sales 2023 | 6.55 x |
P/E ratio 2022 |
-30.1
x | P/E ratio 2023 |
-13.9
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 22.01% |
1 month | -25.00% | ||
3 months | -40.00% | ||
6 months | -45.45% | ||
Current year | -45.45% |
Managers | Title | Age | Since |
---|---|---|---|
Sam Watson
CEO | Chief Executive Officer | - | 23-05-18 |
Rachel Qian
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Peng Ho
CHM | Chairman | 65 | 12-10-29 |
Jason Hine
BRD | Director/Board Member | - | 23-05-18 |
Sam Watson
CEO | Chief Executive Officer | - | 23-05-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 0.006 | 0.00% | 1 083 182 |
24-05-27 | 0.006 | 0.00% | 1,636 |
24-05-24 | 0.006 | 0.00% | 328 |
24-05-23 | 0.006 | 0.00% | 2 |
24-05-21 | 0.006 | 0.00% | 384,817 |
Delayed Quote Australian S.E., May 27, 2024 at 08:36 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-45.45% | 8.17M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.47B | |
-10.87% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- BXN Stock